Sara Engel

Sara Engel

Auto-generated profile, based on publicly available information

Sara Engel

Chr. Hansen A/S, Part of Novonesis, Hørsholm, Denmark

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in The American Journal of Clinical Nutrition
Verified
Journal Article
Closed access
PDF file
SESara Engel
Sara Engel
TTTine Tholstrup
Tine Tholstrup
Background: Butter is known to have a cholesterol-raising effect and, therefore, has often been included as a negative control in dietary studies, whe

11 December 2017 in European Journal of Clinical Nutrition
Verified
Journal Article
Closed access
PDF file
SESara Engel
Sara Engel
MEMie Elhauge
Mie Elhauge
TTTine Tholstrup
Tine Tholstrup


1 March 2014 in Clinical Colorectal Cancer
Verified
Journal Article
Closed access
SRSara Rørvig
Sara Rørvig
NSNis Schlesinger
Nis Schlesinger
NMNina Løth Mårtensson
Nina Løth Mårtensson
SESara Engel
Sara Engel
UEUlla Engel
Ulla Engel
SHSusanne Holck
Susanne Holck

9 April 2025 in Gut Pathogens
Verified
Journal Article
Open access
PDF file
IGIda Marie Bruun Grønbæk
Ida Marie Bruun Grønbæk
SSSofie Sofie
Sofie Sofie
SMSarah Mollerup
Sarah Mollerup
EHEsben Holm Hansen
Esben Holm Hansen
SPSarah Juel Paulsen
Sarah Juel Paulsen
APAndreas Munk Petersen
Andreas Munk Petersen
The aetiology of Crohn’s disease, a chronic inflammatory bowel disease, is multifactorial and not completely understood. However, the association with gut dysbiosis is well-established, and manipulation of the gut microbiota has gained interest as a treatment strategy. This study aimed to investigate the effects of the probiotic strain Bifidobacterium breve, Bif195™ (Bif195) on intestinal inflammation, symptoms, and the gut microbiome composition in patients with small intestinal Crohn’s disease. This was a randomised, double-blind, placebo-controlled trial. Thirty-three patients with small intestinal Crohn’s disease were assigned to eight weeks of treatment with Bif195 or placebo (1:1). The primary outcome was changes in bowel wall thickness measured by intestinal ultrasonography. Other outcomes were changes in symptom severity, quality of life, faecal calprotectin, fatigue, and specific inflammatory parameters on ultrasonography. Changes in the microbiome composition were also examined. Bif195 did not affect the bowel wall thickness in the small intestine compared to placebo. Nor did we observe effects on secondary or clinical explorative outcomes. Analysis of the gut microbiome showed that the relative abundance of B. breve rose during the intervention in the Bif195 group, but the result was statistically non-significant. Surprisingly, we observed a clustering of baseline microbiome data into two groups that differed in several aspects including a statistically significant difference in the incidence of previous bowel resections among the participants. Furthermore, changes in symptom scores after eight weeks of intervention were significantly different across the two microbiome groups, with an interaction effect of p = 0.04. Eight weeks of treatment with Bif195 did not affect clinical outcomes for Crohn’s disease. However, variations in baseline microbiome data influenced the results. This underscores the importance of assessing baseline microbiome data in intervention studies in Crohn’s disease. Clinicaltrials.gov NCT04842149

29 May 2012 in Maternal & Child Nutrition
Verified
Journal Article
Closed access
PDF file
SESara Engel
Sara Engel
KTKathrine Marie Hagerup Tronhjem
Kathrine Marie Hagerup Tronhjem
LHLars Hellgren
Lars Hellgren
KMKim Fleischer Michaelsen
Kim Fleischer Michaelsen
LLLotte Lauritzen
Lotte Lauritzen